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Abstract
Sonic hedgehog (SHH) is a glycoprotein associated with
development that is also expressed in the adult CNS and
released after brain injury. Since the SHH receptors patched
homolog-1 and Smoothened are highly expressed on astro-
cytes, we hypothesized that SHH regulates astrocyte function.
Primary mouse cortical astrocytes derived from embryonic
Swiss mouse cortices, were treated with two chemically distinct
agonists of the SHH pathway, which caused astrocytes to
elongate and proliferate. These changes are accompanied by
decreases in the major astrocyte glutamate transporter-1 and
the astrocyte intermediate ﬁlament protein glial ﬁbrillary acidic
protein. Multisite electrophysiological recordings revealed that
the SHH agonist, smoothened agonist suppressed neuronal
ﬁring in astrocyte-neuron co-cultures and this was abolished by
the astrocyte metabolic inhibitor ethylﬂuoroacetate, revealing
that SHH stimulation of metabolically active astrocytes inﬂu-
ences neuronal ﬁring. Using three-dimensional co-culture,
MAP2 western blotting and immunohistochemistry, we show
that SHH-stimulated astrocytes protect neurons from kainate-
induced cell death. Altogether the results show that SHH
regulation of astrocyte function represents an endogenous
neuroprotective mechanism.
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The hedgehog family of glycoproteins are signalling
molecules with important roles in development and cell
cycle regulation, with Sonic hedgehog (SHH) the only
hedgehog protein expressed in the adult mammalian central
nervous system (CNS) (Echelard et al. 1993; Traiffort et al.
1999). While the developmental implications of SHH
signalling are well documented, only a few reports address
the functional properties of SHH in the adult mammalian
CNS.
SHH in the normal CNS is usually released by neurons
(Sims et al. 2009; Gonzalez-Reyes et al. 2012), with
neuronal SHH able to reduce astrocyte reactivity (Chech-
neva et al. 2014; Chechneva and Deng 2015) and maintain
the proliferative capacity of the neurogenic niche (Sirko
et al. 2013). SHH responsiveness is present in astrocytes in
normal and pathophysiological conditions as both compo-
nents of the SHH membrane signalling complex, patched
(PTCH1) and smoothened, are enriched in astrocytes (Cahoy
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et al. 2008; Zamanian et al. 2012) as is Gli1, a transcription
factor essential for SHH signalling in the adult CNS (Garcia
et al. 2010). Recent evidence using RNAseq identiﬁed Gli1/
2/3 as astrocyte-enriched transcription factors, localizing this
pathway speciﬁcally to astrocytes (Zhang et al. 2014).
Astrocytes are highly responsive to SHH (Atkinson et al.
2009; Yang et al. 2012; Sirko et al. 2013; Pitter et al.
2014). SHH stimulates proliferation of astrocytes as well as
neural progenitor cells and olig2+ cells (Lai et al. 2003;
Amankulor et al. 2009; Bambakidis et al. 2009; Sims et al.
2009). SHH released by neurons or astrocytes may act as a
homeostat, regulating the phenotype of astrocytes, and this
concept has been conﬁrmed recently in the adult CNS
(Farmer et al. 2016). Astrocytes can themselves secrete
SHH after CNS injury (Yang et al. 2012; Pitter et al. 2014)
and since astrocytes are SHH responsive, this signal is likely
to act in a paracrine manner. Thus, SHH is placed to be a
key factor that is involved in neuronal-astrocyte signalling
and regulation of astrocyte phenotype and function. The
functional properties of astrocytes change depending on their
state (Sofroniew 2009). Under normal non-pathological
circumstances, astrocytes possess a number of important
functions including glutathione synthesis and efﬁcient
glutamate uptake via the glutamate transporter (GLT-1)
excitatory amino acid transporter 2 (Damier et al. 1993;
Sofroniew and Vinters 2010). Under pathological condi-
tions, astrocytes change their morphology contributing to
neurodegeneration through increasing the levels of pro-
inﬂammatory cytokines and decreasing the levels of glu-
tathione (John et al. 2004). This change in functional
characteristics is described as a ‘reactive’ phenotype. The
‘reactive’ process involves a gradated change in cellular
function; for example, the levels of glial ﬁbrillary acidic
protein (GFAP), a protein expressed predominantly by
astrocytes, increases as astrocytes become more reactive
giving insight to the level of reactivity (Middeldorp and Hol
2011). The idea of astrocyte ‘reactivity’ is changing,
however, with recent research showing vast genetic hetero-
geneity between different types of injury; suggesting that
classical markers such as shape change or GFAP
immunoﬂuorescence may be superseded by distinct patterns
of gene transcription, speciﬁc to the type of injury (Zama-
nian et al. 2012). Indeed astrocytes have recently been
classiﬁed as A1 or A2 based on their transcriptomic proﬁles
after two distinct CNS injuries (Liddelow et al., 2017). A1
astrocytes are induced through microglial secretion of
interleukin 1, tumour necrosis factor and C1q. These
astrocytes become reactive and lose their ability to support
neurons. A2 astrocytes, however, were thought to be
protective as a result of their up-regulation of neurotrophic
factors after intraperitoneal lipopolysaccharide injection.
This may help to disseminate the functional changes
between normal and reactive astrocytes identifying whether
reactive astrocytes gain ‘function’ or gain ‘detrimental
effects’ dependant on the type of pathology (Sofroniew
and Vinters 2010).
SHH signalling has been shown to contribute to both L-
glutamate and ATP release in cultured cerebellar astrocytes,
identifying the importance of SHH in neuro-glial interactions
(Okuda et al. 2016). SHH has been reported to be neuropro-
tective in animal models of Parkinson’s Disease (Miao et al.
1997; Dass et al. 2002; Hurtado-Lorenzo et al. 2004). The
protective properties of SHHhave been described in the context
of ischaemia (stroke), where small molecule agonists of this
pathway have been shown to ameliorate some of the patholog-
ical features (Dellovade et al. 2006). Evidence now shows that
stimulating the SHH pathway in mice days after induction of
stroke, promotes repair, reduces infarct size and reduces
reactive astrogliosis, namely astrocyte hypertrophy and
increased deposition ofGFAP (Chechneva et al. 2014). Recent
evidence has shown that after glutamate induced excitotoxicity,
nNos translocates to the nucleus and induces SHH transcription
via Sox2 (Zhang et al. 2016), suggesting a speciﬁc link
between SHH effects on astrocytes and neuroprotection.
Given that SHH reduces astrocyte reactivity in vivo, our
aim was to understand what effect SHH agonists have on
astrocyte morphology and on two markers of mature
astrocytes, GFAP and GLT-1. Furthermore, we aimed to
investigate the link between SHH signalling, astrocyte
reactivity and neuronal function using well-established
in vitro model systems and multielectrode array. Our data
show SHH signalling transforms astrocytes, and potentiates a
biochemically protective phenotype that suppresses neuronal
hyperexcitability and confers neuroprotection against an
excitotoxic insult.
Materials and methods
Animal groups
Timed mated female Swiss mice (Harlan UK) (RRID:
IMSR_CRL:24) were maintained and killed in accordance with
the UK Animals (Scientiﬁc Procedures) Act (1986). Animals were
killed using cervical dislocation, according to Home Ofﬁce guide-
lines. Cerebral cortices from embryonic day 15 mouse embryos
were obtained and cells were isolated via mechanical disassociation
as previously described (Ugbode et al. 2014).
Cell culture and multielectrode array
Conventional (two-dimensional) primary cortical astrocyte, cortical
neuron and cortical astrocyte-neuron co-cultures were prepared as
previously described (Bahia et al. 2012; Ugbode et al. 2014). For
three-dimensional (3D) transwell experiments, primary cortical
astrocytes were seeded on Alvetex 6- and 12-well hanging inserts
(Reinnervate, Durham, UK) as previously described (Ugbode et al.
2016). The primary astrocyte cultures were of 95% purity. The
remaining 5% consist of microglia and immature neurons. The
astrocyte-neuron cultures consist of 55% astrocytes to 40% neurons.
The remaining 5% consist of microglia. Primary neuron cultures
contained 90% neurons to 10% astrocytes. This is based on staining
using CD68/ionized calcium-binding adapter molecule 1 for
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microglia, GFAP/S100b for astrocytes, b-3 tubulin/Tau/micro-
tubule-associated protein 2 (MAP2)/NeuN/Doublecortin staining
for neurons (Data not shown).
For electrophysiological studies, primary neuron and astrocyte-
neuron co-cultures were seeded on 60 channel (30 lm electrode
diameter, 200 lm electrode spacing) planar multielectrode arrays
(MEAs;60MEA100/10iR-Ti-gr – Multi Channel Systems, Reutlin-
gen, Germany), as described previously (Hammond et al. 2013).
MEAs were dried under UV light, coated in poly-D-lysine (0.1 mg/
mL; Merck-Millipore, Billerica, MA, USA) for 5 min, dried again
and incubated overnight in 10% foetal bovine serum. Cells were
plated at a density of 1 9 106 per MEA and 50% media were
exchanged every 3 days. At DIV 18, extracellular electrophysio-
logical recordings (at least 300 s) were made from these cultures
under control and drug-treated conditions. For concentration-
response experiments, an equilibration period of 200 s following
drug application was observed between any treatment and the start
of the recording. Astrocytes were metabolically inhibited using
ethylﬂuoroacetate (EFA; 1 mM; 1 h; Sigma, St Louis, MO, USA –
Cat No: 163813), a derivative of ﬂuoroacetate that acts as a
metabolic toxin that prevents the conversion of citrate to isocitrate,
inhibiting the tricarboxylic acid cycle (Clarke 1991).
MEA data were simultaneously recorded at 10 kHz/channel using
MC_Rack (Multi-Channel Systems, v4.3.5) and analysed by replay
in the same software where raw data were high-pass (200 Hz)
ﬁltered and spikes detected and re-recorded using a threshold of
5.5 standard deviations from RMS noise. Spike trains were
imported to NeuroExplorer software (Nex Technologies, Madison,
AL, USA; version 4.088) where active electrodes (> 100 spikes
recorded in a 300 s period in control conditions) were selected for
further analysis. Spike rate histograms were constructed using
NeuroExplorer for 300 s recordings in conditions examined and
mean ﬁring frequency for each electrode derived. Only data
obtained from electrodes that were active through all conditions of
the experiment were included in the analysis. The number of
electrodes from each biological replicate was of a similar number
(7–8 electrodes per experiment). Statistical analysis was done on
pooled signals from each replicate experiment (i.e. n = 3).
MTT assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay for cell viability was carried out as previously
described (Ugbode et al. 2014). After treatment, primary mouse
astrocytes were washed with HBM buffer and incubated with
500 lL of MTT buffer (0.5 mg/mL Thiazoyl Blue Tetrazolium
Bromide (Sigma) in HBM) at 37°C for 1 h. The formazan
precipitate was solubilized with 300 lL dimethylsulfoxide per well;
200 lL from each well was transferred to a 96-well plate and
absorbance measured using a plate reader (Flexstation 3; Molecular
Devices, Palo Alto, CA, USA, k = 490 nm).
Immunofluorescence and cell imaging
Cells were treated with different compounds, washed and ﬁxed for
30 min at room temperature (22°C) with 4% paraformaldehyde
(Sigma) dissolved in phosphate-buffered saline (PBS). After ﬁxa-
tion, cells were blocked and permeabilized in 1% normal goat serum
(NGS; Sigma) and 0.2% Triton-X (Sigma) in PBS, for 1 h at room
temperature (22°C). We used a polyclonal rabbit anti-mouse GFAP
primary antibody (Z0334; Dako, Carpinteria, CA, USA, UK,
0.6 lg/mL) or a monoclonal anti-mouse MAP-2 antibody (Cat no:
836201; Biolegend, San Diego, CA, USA. 1 : 1000) in PBS
containing 1% NGS (PBS/NGS), allowing 1 mL per coverslip (12-
well plate) incubated overnight at 4°C.
Corresponding secondary antibodies were added (goat anti-rabbit/
mouse Alexaﬂuors 488 and 568 in PBS/NGS, 2 lg/mL) for
immunoﬂuorescence (Life Technologies, Grand Island, NY, USA)
incubating for 90 min, at room temperature 22C. Cells were then
incubated with Hoescht 33342 (4 lg/mL; Life Technologies),
washed with PBS and mounted using Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA).
To assay cell proliferation, cells were incubated with anti-Ki-67
antibody (primary polyclonal rabbit anti-mouse, 1 : 1000; Abcam
ab66155, Cambridge, UK) along with a goat anti-rabbit secondary
conjugated to Alexaﬂuor 488 following the above method. Antigen
retrieval was carried out by incubation with citric acid (pH 6.0,
0.01M) for 1 h at 37°C before adding the primary antibody. To
monitor proliferation, six images were analysed per condition
(coverslips) across four independent experiments.
Images were collected on an (Zeiss Axioskop 2, Oberkochen,
Germany) upright microscope using 109/209 and 409 Plan-
NeoFluar objectives, using Zeiss Filter Sets 02/10 and 15 for 4,6-
Diamidino-2-phenylindole, dihydrochloride (DAPI)/FITC/Rho-
damine. Images were processed using Axiovision Software (Zeiss)
and quantitative measurements performed using ImageJ (1.43 u)
(Image J Bethesda MD, USA). High resolution images were
prepared using Photoshop CS3.
The resource identiﬁers for the primary and secondary antibodies
are as follows: Primary Antibodies GFAP: Dako Cat# Z0334 RRID:
AB_10013382; MAP2: Covance Research Products Inc Cat# SMI-
52R-100 RRID:AB_510028, Bethesda, MD, USA; Ki-67: Abcam
Cat# ab66155 RRID:AB_1140752; GAPDH: Thermo Fisher Sci-
entiﬁc Cat# AM4300 RRID:AB_2536381, Waltham, MA, USA,
Waltham, MA, USA; Secondary Antibodes: Goat anti-Mouse 488
Alexa Fluor: Thermo Fisher Scientiﬁc Cat# A-11001 RRID:
AB_2534069; Goat anti-Mouse 546 Alexa Fluor: Thermo Fisher
Scientiﬁc Cat# A-11003 RRID:AB_2534071; Goat anti-Rabbit 488
Alexa Fluor: Thermo Fisher Scientiﬁc Cat# A-11034 also A11034
RRID:AB_2576217; Goat anti-Rabbit 546 Alexa Fluor: Thermo
Fisher Scientiﬁc Cat# A-11010 RRID:AB_2534077.
Time lapse microscopy and morphometric analysis
For time lapse microscopy, we used a Nikon ECLIPSE TE200
upright time lapse microscope and complementary Nikon NIS-
Elements (4.0) software, Kingson Upon Thames, UK was used to
assay morphological changes. After cell treatment, the plate was
placed in a heated chamber (37°C and 5% CO2) and ﬁxed to the
microscope platform. Images were taken once every 10 min for 24 h,
generating 144 TIFF ﬁles. All collected images from an individual
well formed an ND2 ﬁle, which was then opened in ImageJ, and
saved as an AVI ﬁle allowing video playback. Individual frames
were assembled into ﬁgures using Photoshop CS3. At the end of the
time lapse, the cells were removed from the heated chamber, washed
and ﬁxed for further immunohistochemical investigation.
The NeuronJ plugin for ImageJ was used to measure the length of
astrocytes. Brieﬂy, TIFF ﬁles generated as mentioned above and
individual images at speciﬁc time points (every 4 h from 0 to 24 h)
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were thresholded and astrocyte length calculated. Values were
combined and average astrocyte length calculated. Twenty astro-
cytes were measured at each time point and three videos per
treatment were analysed (Figure S1).
Western blotting
Western blotting was carried out as previously described (Ugbode
et al. 2014). Primary antibodies for GFAP (1 : 5000), GLT-1
(monoclonal rabbit anti-mouse – 1 : 10 000 – provided by Prof.
David Pow, RMIT University), MAP2 (monoclonal anti-mouse
1 : 1000; Biolegend, San Diego, CA, USA – 836201) and GAPDH
(monoclonal goat anti-mouse – 1 : 10 000; Life Technologies) were
incubated overnight at 4°C in Tween/Tris buffered salt solution
(TTBS) (20 mM tris buffer (pH 7.5; Sigma) containing 0.4% Tween-
20 (Sigma) and 1% non-fat milk powder). Goat antirabbit/goat
antimouse secondary antibodies conjugated to horseradish peroxidase
(Sigma) were used at 1 : 5000 prior to detection with enhanced
chemiluminescence reagent (Clarity; Biorad, Hemel Hempstead,
UK). Molecular weight markers (Biorad Prestained Dual Xtra
Standards) were run alongside lysates and GAPDH protein levels
were used as a loading control. Blots were imaged using the Chemidoc
MP imaging system (Biorad) for chemiluminescence and analysed by
the corresponding ImageLab software (Biorad). Images were
exported from the software at a resolution of 600 dpi into photoshop
CS3 and processed into ﬁgures.
Quantitative PCR
RNA was extracted using RNA Bee (AMS Biotechnology,
Abingdon, UK) according to manufacturer instructions. All RNA
samples were derived from cells growing in six-well plates
(8 9 105cells per well). RNA concentrations were calculated using
a NanoDrop 2000 spectrophotometer (Thermo Fischer Scientiﬁc). A
high-capacity cDNA kit (4368814; Life Technologies) was used to
transcribe 2 lg of RNA. To perform qPCR, cDNA was diluted
1 : 20 in Tris-EDTA buffer (Sigma) and 5 lL of cDNA was
combined with 1 lL of both the forward and reverse primers
(2.5 lM) and 7 lL of SYBR green master mix (cat no: 204141 –
QuantiTect SYBR Green PCR Kit; Qiagen, Valencia, CA, USA) to
create a 14 lL reaction volume per well. Oligonucleotide sequences
were created using Primer3 (Koressaar and Remm, 2007) and
PUBMED websites and custom synthesized (Sigma). Primers were
re-suspended in nuclease-free water, to a concentration of 2.5 lM.
All primers were validated using a primer efﬁciency test before use.
All oligonucleotides here have an efﬁciency ≥ 90%. Primer
sequences for Gli-1 (ID number: 90186272b1), Gli-2
(124487480b1), Gli-3 (120953172b1), GLT-1 (227330634c1) and
GAPDH (12601253861) were obtained from PrimerBank (Spandi-
dos et al. 2010) and oligonucleotides for ampliﬁcation of GFAP and
PTCH1 were designed from the published sequences as follows,
GFAP: (F) 50-GGTGAGCCTGTATTGGGACA-30 (bases) and (R)
50-TTTCTCCAACCTCCAGATCC-30 (bases 1223 – 1335, frag-
ment size 112 base pairs); PTCH1: (F) 50-CACAGCAACAGT-
CACCGAA-30 (bases 3012-3032) and (R) 50-GTTCTCACAACC
CTCGGAAC-30 (bases 3992 – 4101, fragment size 118 base pairs).
Aconitase assay
To assay the activity of mitochondrial aconitase, we used an
aconitase activity kit (ab83459; Abcam), in accordance with the
manufacturer’s instructions. Primary astrocytes and neurons in six-
well plates were treated with 200 lL media or 200 lL of
ethylﬂuoroacetate EFA for 1 h. After treatment, cells were homog-
enized in 100 lL of assay buffer provided and spun at 20,000 g for
15 min at 4°C, to separate the mitochondrial fractions. The pellet
was re-suspended with 100 lL of assay buffer and sonicated for
20 s. Samples were then incubated for 1 h with the substrate
mixture at 25°C. Afterwards, 10 lL of developer was added to each
sample, incubated at 25°C for 10 min and the absorbance was
measured using a plate reader (Flexstation 3; Molecular Devices.
k = 450 nm). Absorbance was then compared to an isocitrate
standard curve.
MAP2 assay
MAP2 protein levels were used to assay kainate-induced neurode-
generation. To assay the effect of SHH-sensitive astrocytes on
neurons, we used 3D Alvetex scaffolds to culture primary
astrocytes. The astrocytes were seeded into the scaffold and after
11–12 DIV, the 3D well inserts were treated with smoothened
agonist (SAG) (1 lM) for 4 h and along with untreated 3D
scaffolds, were washed twice with PBS and then incubated with
cultures of primary neurons (14–18 DIV) for 24 h. After 24 h,
inserts were removed and the neurons were incubated with 100 lM
kainic acid for 24 h. Cells were either ﬁxed in paraformaldehyde
and used in immunohistochemistry or lysed and used for western
blotting. Images obtained after MAP2 staining were thresholded and
quantiﬁed using Volocity software (Edition 6.2; Perkin Elmer,
Waltham, MA. USA).
Drug concentrations
Concentration-response experiments for SAG/purmorphamine
(Pur)/Cyclopamine were carried out using time lapse microscopy
(data not shown). Furthermore, drug toxicity was assayed in mixed
cultures using multielectrode array. Our time course experiments
were based on previously published in vitro experiments on cultured
neurospheres (Sirko et al. 2013) and astrocytes (Atkinson et al.
2009). Kainic acid-induced neurodegeneration has been previously
characterized in our laboratory and chosen concentrations were
informed by published literature (Wang et al. 2005).
Statistical analyses
Statistical signiﬁcance was derived using one-way ANOVA followed
by Dunnett’s multiple comparison post hoc test unless otherwise
stated (Prism 6; GraphPad Software, San Diego, CA, USA).
Results
Sonic hedgehog pathway activation causes elongation and
proliferation of primary mouse astrocytes
To analyse SHH pathway stimulation in primary astrocytes,
we used two chemically distinct agonists, Pur and SAG, to
induce pathway stimulation in primary astrocytes through
the smoothened receptor (Chen et al. 2002; Sinha and Chen
2006). Time lapse and ﬂuorescence microscopy showed that
Pur and SAG caused astrocytes to elongate (Fig. 1). Both
agonists displayed different time and concentration depen-
dence, with SAG (elongation after 1 h) acting more rapidly
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than Pur (4–12 h). Furthermore, at 10 lM, SAG induced a
persistent elongation over 24 h in comparison to Pur
(Figure S1). In contrast, no obvious changes to morphology
were observed under treatments with the SHH pathway
antagonist, cyclopamine (data not shown).
SHH agonists cause cell proliferation
Next, we monitored astrocyte viability and proliferation
following SHH pathway stimulation. We ﬁrst used MTT
turnover as a biochemical readout of cellular viability. Using
analysis of variance (ANOVA, F = 1.4, p = 0.31) followed by
Dunnett’s post hoc test, no signiﬁcant differences were
observed between SAG- and Pur-treated cells (10 lM) when
compared to untreated controls (Fig. 2a and b) at either 24
(SAG; 3.2  0.08, p = 0.1762; Pur; 3.3  0.05,
p = 0.5982, DF = 8, n = 3) or 72 h (SAG; 3.3  0.1,
p = 0.565; Pur; 3.3  0.1, p = 0.0535, DF = 8, n = 3),
supporting evidence from time lapse microscopy that shows
no cellular toxicity following agonist exposure.
Since the SHH pathway is known to be mitogenic, we
used anti-Ki-67 antibodies to monitor astrocyte prolifera-
tion following treatment with the SHH agonists (Fig. 2c).
We observed a signiﬁcant increase (F = 32, DF = 86,
p = 0.0001) compared to vehicle-treated controls in the
number of dividing cells per ﬁeld under both SAG
(100 nM; 29.3  3 cells, p < 0.0001 and 10 lM;
56.3  5.9 cells, p < 0.0001, n = 4) and Pur (100 nM;
27.4  1.8 cells, p = 0.0005 and 10 lM; 54.7  1.2 cells,
p < 0.0001, n = 4) as analysed by one-way ANOVA fol-
lowed by Dunnett’s post hoc test.
To conﬁrm that agonists were acting on the SHH signalling
pathway, we carried out qPCR to measure the mRNA levels
(a) (f) (k) (p) (u)
(b) (g) (l) (q) (v)
(c) (h) (m) (r) (w)
(d) (i) (n) (s) (x)
(e) (j) (o) (t) (y)
Fig. 1 Sonic hedgehog (SHH) pathway agonists cause astrocyte
elongation over time. Phase contrast time lapse microscopy identiﬁes
morphological changes in primary mouse astrocytes (embryonic day
15, 12 DIV) treated with SHH agonists, Smoothened agonist (SAG)
and Pur (purmorphamine). Astrocytes were visualized following vehicle
administration (a–d), or the SHH agonists SAG (f–i and k–n) or Pur (p–s
and u–x). Cultures were also ﬁxed and immunostained for glial ﬁbrillary
acidic protein (GFAP) (Green e, j, o, t, y). Over 24 h, astrocytes begin
to elongate showing morphological changes indicative of a transition to
a less reactive (de-differentiated) state. Note the change from
cobblestone shape to more elongated morphologies. White boxes
shows zoomed cells, highlighting change in morphology of those cells
over time. The phenotypic change was evident between 4 and 8 h for
purmorphamine and within 1 h for SAG. Scale bar = 10 lm.
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of the main transcription factor recruited following Smo
signalling, Gli1, along with other transcripts associated with
hedgehog signalling. Stimulating the SHH pathway revealed
signiﬁcantly increased Gli1 mRNA following 24 h treat-
ments with Pur (5.4  1.8-fold increase, F = 5.6,
p = 0.0010, DF = 56, n = 6) and SAG (2.3  0.03-fold
increase, F = 5.8, DF = 41, p = 0.0022, n = 6). Pur and
SAG did not change Gli2 or Gli3 mRNAs. Levels of
mRNA for PTCH1, the transmembrane receptor which
inhibits Smo activation, increases after both Pur (4.1-
fold  1.9, F = 5.6, p = 0.0352, DF = 56, n = 6) and
SAG (2.5-fold  0.8 increase, F = 5.8, p = 0.002,
DF = 41, n = 6) treatments (Fig. 3a).
We also treated primary mouse astrocytes with cyclopa-
mine, a SHH pathway antagonist (10 lM, 24 h) (Fig. 3a).
Gli1 mRNA levels determined by qPCR were signiﬁcantly
reduced (0.94-fold  0.01 decrease, F = 9.1, p = 0.0004,
DF = 26, n = 5) as determined by one-way ANOVA followed
by Dunnett’s post hoc test. This result shows there is tonic
SHH signalling in astrocyte cultures.
Fig. 2 Sonic hedgehog pathway stimulation causes astrocyte prolif-
eration. Smoothened agonist (SAG) and purmorphamine (Pur – both
10 lM) do not change 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) turnover at 24 (a) or 72 (b) hours in primary mouse
astrocyte cultures (embryonic day 15, 12 DIV). Immunostaining (c) for
Ki67 (green), a marker of cell division reveals increased astrocyte
proliferation with both agonists. Scale bar = 20 lm. Statistical analysis
was carried out using one-way analysis of variance (ANOVA) followed by
Dunnett’s post hoc test (*p<0.05, **p<0.01, ***p < 0.001). Error bars
represent standard error of the mean (SEM). N = 3 independent
cultures.
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Fig. 3 Sonic hedgehog pathway stimulation increases Gli1 mRNA and
decreases astrocyte hallmarks glutamate transporter 1 (GLT-1) and
glial ﬁbrillary acidic protein (GFAP). qPCR and western blotting was
carried out for a number of mature astrocyte markers using cDNA and
protein samples from murine embryonic (embryonic day 15) cortical
astrocytes (12 DIV). (a) qPCR shows both agonists signiﬁcantly
increase Gli1 mRNA with smoothened agonist (SAG) further increas-
ing patched homolog 1 (PTCH1) and smoothened receptor (SMO)
mRNA. Pur (Purmorphamine, 10 lM) also signiﬁcantly increases
PTCH1 mRNA. The antagonist cyclopamine signiﬁcantly reduces
Gli1 mRNA. Panel b shows GLT-1 (trimer 160 kDa and monomer
65 kDa) protein levels after time course treatments with SAG (10 lM).
GLT-1 protein levels signiﬁcantly decrease after 12 h treatment with
SAG. Panel d shows (GFAP, 50 kDa) protein levels after time course
SAG (10 lM) treatments. GFAP protein levels are signiﬁcantly
reduced after 24 h SAG treatment. Glyceraldehyde Phosphate Dehy-
drogenase (GAPDH) was used as a sample loading control. GLT-1 (c)
and GFAP (e) protein levels were quantiﬁed by normalizing to GAPDH.
Protein levels after treatment are expressed as a % of the untreated
control protein levels (red line). Statistical analysis was carried out
using ANOVA (analysis of variance). (f) qPCR shows 24 h treatments
with either SAG (10 lM) or Pur (10 lM) signiﬁcantly increase GLT-1
mRNA, while GFAP mRNA remains unchanged. mRNA changes
analysed through relative quantiﬁcation (RQ) and are depicted as the
mean compared to untreated controls (red line). GAPDH was used as
a reference gene during relative quantiﬁcation of CT values. Statistical
analysis was carried out using ANOVA followed by Dunnett’s post hoc
test (*p < 0.05, **p < 0.01, ***p < 0.001). Error bars represent
standard error of the mean (SEM). N = 5 biological replicates for both
western blotting and qPCR data.
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SHH agonists down-regulate GLT-1 and GFAP protein levels
SHH pathway stimulation has previously been shown to
transform astrocytes, correlating with a decrease in GFAP
(Yang et al. 2012; Sirko et al. 2013); however, there are no
reports on expression of the glutamate transporter, GLT-1, an
abundant CNS protein which is a marker of mature astrocytes.
Using western blotting, we found SAG (10 lM) signiﬁcantly
reduced GLT-1 after 12 h (42.6  8.5% decrease, F = 6.4,
p = 0.0085, DF = 12, n = 5) with levels returning to control
levels at 24 h (Fig. 3b and c) as determined by one-way ANOVA
followed by Dunnett’s post hoc test. Purmorphamine (10 lM)
also reducedGLT-1, but the knockdownwas only evident after
24 h (50.2  9% decrease, p = 0.010, DF = 8, n = 5, Stu-
dents t-test; data not shown), consistent with the slower effect
of Pur compared to SAG on astrocyte morphological changes.
Both SAG and Pur caused signiﬁcant decreases in the levels of
GFAP (Fig. 3d and e) (F = 4.3, p = 0.03, ANOVA). SAG
(10 lM, 24 h) caused 28.7  8.8% decrease compared to
controls (p = 0.0325, DF = 17, n = 5), and Pur (10 lM,
24 h) caused 51  9% decrease compared to controls
(F = 7.4, p = 0.0027, DF = 8, n = 5).
In order to explore whether GFAP and GLT-1 mRNA
correlated with protein levels, we also assayed GFAP and
GLT-1 transcripts using qPCR (Fig. 3f). GFAP mRNA
showed no statistical differences between control and treated
cells, indicating that the loss of GFAP protein was post-
transcriptional. Signiﬁcant increases in GLT-1 mRNA were
observed following treatment of astrocytes with Pur
(0.51  0.2-fold increase p = 0.0322, DF = 11, n = 4) or
SAG (0.95  0.2-fold increase, p = 0.0004, DF = 11,
n = 4) after 24 h, suggesting that the increase in GLT-1
protein between 12 and 24 h was caused by enhanced
availability of GLT-1 mRNA.
Smoothened agonist signals via astrocytes to decrease
neuronal firing
Having shown that activation of SHH signalling pathways
caused changes in levels of key astrocyte proteins which
accompanied the morphological changes, we addressed the
functional consequences of SHH pathway activation. To test
how SHH treatment of astrocytes affects neurons, we used
MEA to allow simultaneous electrophysiological recordings
from up to 60 electrodes onto which neurons are cultured
(Hammond et al. 2013). We cultured primary cortical
neurons and astrocyte-neuron co-cultures and observed the
effect of pathway stimulation upon neuronal ﬁring frequency.
To account for potential effects of neuronal toxicity on
electrophysiological readouts, we generated timed matched
cultures for immunohistochemistry. Using MAP2 staining,
we found that low (100 nM, 24 h) concentrations of SAG
have no effect on neuronal viability in neurons (Fig. 4b)
alone or in astrocyte-neuron co-cultures (Fig. 4e), whereas
high concentrations at long exposures (10 lM, 24 h) kill
neurons in both neuronal cultures (Fig. 4c) and co-cultures
(Fig. 4f). This allowed the concentration range and exposure
time to be chosen for MEA experiments. SAG was used for
all electrophysiology experiments because of its solubility in
saline as Pur is only soluble in dimethylsulfoxide, a vehicle
that can affect neuronal ﬁring in its own right in MEA
experiments (data not shown).
In primary cortical neuron cultures (18 DIV), SAG (after
5 min incubation) produced a statistically signiﬁcant concen-
tration-dependent increase in ﬁring frequency (Fig. 4h). At
100 nM, SAG caused 30.3  8.7% increase (F = 27.6,
p = 0.0121, DF = 143 n = 3), at 1 lM a 49  13.2%
increase (F = 27.6, p < 0.0001, DF = 143, n = 3) and at
10 lM, a 103  15.6% increase (F = 27.6, p < 0.0001,
DF = 143, n = 3). Data represent 24 active electrodes across
three biological replicates. Conversely, in co-cultures contain-
ing astrocytes, SAG did not increase neuronal ﬁring frequency
(Fig. 4k). Here, neuronal ﬁring frequency was signiﬁcantly
decreased compared to vehicle-treated controls 5 min follow-
ing 1 nM SAG (F = 16, 36.3  4.2% decrease, p < 0.0001,
DF = 167, n = 3), 10 nM (F = 16, 35.3  5.2% decrease,
p = 0.0001, DF = 167, n = 3) and 100 nM (F = 16,
31.2  5.6% decrease, p = 0.0009, DF = 167, n = 3) con-
centrations of SAG. However, at higher concentrations of
SAG, the previously detected signiﬁcant decreases in neuronal
Fig. 4 Smoothened agonist acts through astrocytes to reduce neu-
ronal ﬁring frequency. Immunohistochemistry showing glial ﬁbrillary
acidic protein (GFAP – green) and MAP2 (microtubule-associated
protein 2 – red) expression in primary cortical neurons (a–c) or
astrocyte-neuron cultures (d–f). Low concentrations of smoothened
agonist (SAG) do not visibly alter either culture (b and e). High
concentrations of SAG (10 lM) cause neuronal cell death in both
neurons (c) and astrocyte-neuron cultures (f). Scale bar = 100 lm.
Multielectrode array (MEA) recording of neuronal spike ﬁring activity
reveals that the effect of SAG upon neurons is mediated by astrocytes.
In neuron only cultures (g) SAG increases neuronal ﬁring in a
concentration-dependent manner (h). Insets show 200 spike overlay
(light grey) and average spike waveform (white) in control, 10 nM and
10 lM conditions. Scale: 20 lV, 10 ms. Representative traces (i)
demonstrate concentration-dependent increases in spike ﬁring. Scale:
20 lV. 250 ms. In astrocyte-neuron cultures (j), astrocytes bind SAG
which leads to a decrease in neuronal ﬁring (k). Insets show 200 spike
overlay (light grey) and average spike waveform (white) in control,
10 nM and 10 lM conditions. Scale: 10 lV, 10 ms. Higher concen-
trations (10 lM) cause ﬁring frequency to increase back to 100% of
control suggesting that astrocytes have limited capacity to bind the
agonist. Representative traces (L) demonstrate concentration-depen-
dent decreases in spike ﬁring. Scale: 10 lV. 250 ms. Scale
bar = 10 lm. Signiﬁcance was derived using analysis of variance
(ANOVA) followed by Dunnett’s post hoc test (*p<0.05, **p<0.01,
***p < 0.001). Error bars represent standard error of the mean (SEM).
N = 3 independent cultures. Data for each replicate culture is from 7 to
9 active electrodes.
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ﬁring frequency were no longer evident (1 lM; 8.8  6%
decrease, p = 0.7587, n = 3 and 10 lM;1.9  9.5%decrease,
p = 0.9997, n = 3.). We note that, in support of our immuno-
histochemical data, the highest concentration of SAG (10 lM)
when applied for 1 h or more, caused a large decrease in
neuronal ﬁring frequency in co-cultures (10 lM SAG, 1 h;
63  8.4% decrease compared to control, F = 16,
p < 0.0001, DF = 167, n = 3) indicative of toxicity.
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
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Metabolic inhibition of astrocytes abolishes SHH signalling
to neurons
That SAG caused elevated neuronal ﬁring in neuron
cultures, but not in astrocyte-neuron co-cultures could mean
that astrocytes are binding SAG passively so that less
agonist reaches neurons or that SAG binding to astrocytes
causes them to actively suppress neuronal ﬁring. In order to
distinguish between these possibilities, we chose to
metabolically inhibit astrocytes. We used EFA which is a
selective metabolic inhibitor of astrocytes (Hassel et al.
1992).
Time matched cultures of primary astrocytes and primary
neurons were prepared, treated with EFA (1 mM, 1 h) and
stained for GFAP and MAP2. Primary astrocytes (Fig. 5b)
and neurons (Fig. 5d) show no differences under EFA
indicating that EFA does not cause cell death under these
conditions. In order to demonstrate that astrocyte metabolism
is preferentially inhibited under EFA, we applied EFA for
1 h (1 mM) to pure cultures of primary astrocytes and
primary neurons and then assayed the activity of aconitase
and compared the activity between cultures. We observed a
statistically signiﬁcant decrease in aconitase activity in
astrocytes (51  8.6% decrease, p = 0.0079, n = 4) but
not in primary neurons (28  18% decrease, p = 0.1534,
n = 4), as determined by one-way ANOVA (Fig. 5e). This
shows that astrocytic aconitase is preferentially inhibited by
EFA over neuronal aconitase.
We then treated co-cultures with EFA for 1 h and further
treated the MEA’s with 100 nM SAG or vehicle and
measured neuronal ﬁring frequency 5 min after drug appli-
cation and then over the following hour. This experiment
allowed us to test both the effect of EFA on ﬁring frequency
and also observe differences in ﬁring frequency between
EFA (1 h) and EFA and SAG (100 nM, 1 h). EFA alone
causes a signiﬁcant increase in ﬁring frequency compared to
controls (F = 6, 75  22%, p = 0.0222, DF = 169, n = 3),
indicating metabolic suppression of astrocytes causes some
hyperexcitability. The addition of SAG to EFA-treated
astrocytes, rather than causing a suppression in ﬁring
frequency as previously shown, caused a statistically signif-
icant increase in ﬁring frequency compared to controls
(F = 6, 98  29% increase, p = 0.0024, DF = 169, n = 3)
as determined by one-way ANOVA followed by Dunnett’s
multiple comparison test (Fig. 5f).
(a) (b)
(c) (d)
(e)
(f)
Fig. 5 Neuronal ﬁring properties in smoothened agonist (SAG)-treated
co-cultures are dependent on metabolically active astrocytes. Immuno-
histochemistry showing glial ﬁbrillary acidic protein (GFAP – green)
expression in primary astrocytes (a and b) and MAP2 (microtubule-
associated protein 2 – red) expression in primary cortical neuron
cultures (c and d). Ethylﬂuoroacetate (EFA, 1 mM, 1 h) does not visibly
change astrocytes (b) or neuronal (d) cultures when compared to
controls (a and c). Furthermore, EFA (1 mM, 1 h) signiﬁcantly reduces
mitochondrial aconitase activity in astrocytes (e). While EFA decreases
aconitase activity in neurons, the observed decrease was not
statistically signiﬁcant. N = 5 independent cultures. Finally, multielec-
trode arrays (MEA’s) were treated with EFA and then SAG (100 nM).
EFA alone signiﬁcantly increases ﬁring frequency in co-cultures. This
increase in ﬁring rate is further enhanced following immediate
incubation with SAG (smoothened agonist, 100 nM) when compared
to controls (red line). Statistical analysis carried out using one-way
ANOVA followed by Dunnett’s multiple comparison test (*p < 0.05,
**p < 0.01)). Error bars represent standard error of the mean (SEM).
N = 3. Scale bar = 10 lm. Data represent 56 active electrodes across
three biological replicates.
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SHH sensitive astrocytes reduce kainate-induced
neurodegeneration
Since SAG treatment of astrocytes causes suppression of
neuronal ﬁring frequency, we wished to test whether this was
associated with neuroprotection. We cultured primary astro-
cytes in Alvetex transwell inserts, allowing us to ﬁrst
stimulate astrocytes with SAG away from neurons, and
following washout of SAG, allow the astrocytes to condition
neuronal media without physical contact between astrocytes
and neurons. We have previously characterized the properties
of astrocytes cultured in 3D Alvetex transwell inserts
(Ugbode et al., 2016). Primary astrocyte cultures (12 DIV)
were left untreated, or treated with 1 lM SAG for 4 h. After
treatments, the 3D transwells were washed twice with PBS to
remove any SAG present in the astrocyte medium. The
astrocyte transwells were then placed over wells containing
primary neuronal cultures (14–18 DIV) for 24 h, to allow the
astrocytes to condition the media. After 24 h, the transwells
were removed and the neurons were incubated with 100 lM
kainic acid for 24 h and neuronal viability was assayed using
western blotting and immunohistochemistry for the mature
neuron marker, MAP2.
Using western blotting, we found that kainic acid (100 lM,
24 h) signiﬁcantly reduced MAP2 protein levels in primary
neuronal cultures (90  5% decrease, p = 0.0001, DF = 4,
n = 3) when compared to vehicle controls. Comparing
neurons conditioned with astrocytes on transwells to neurons
which had been cultured with transwells and then treated with
kainic acid (100 lM), using western blotting, we found that
kainic acid also signiﬁcantly reduced MAP2 protein levels of
neurons (84.4  4.6% decrease, p = 0.0003, DF = 4, n = 3).
Neurons which had been conditioned with SAG-treated
astrocytes (1 lM, 4 h) also displayed neuronal death follow-
ing kainate treatment compared to vehicle control: MAP2
protein levels were 60  12% decreased (p < 0.001, DF = 4,
n = 3) compared to neurons conditioned with untreated
astrocytes. However, SHH treatment of astrocytes caused
attenuation of neuronal death: comparing neurons conditioned
with SHH-treated astrocytes and then treated with kainic acid
to neurons conditioned with untreated astrocytes and then
treated with kainic acid, we observed signiﬁcantly higher
levels of MAP2 (24  3% increase, p = 0.0235, DF = 4,
n = 3). These data show that SHH-sensitive astrocytes reduce
kainic acid-induced neurodegeneration (Fig. 6a and b).
Fig. 6 Sonic hedgehog (SHH)-treated astrocytes delay kainate-
induced neurodegeneration in vitro. Western blotting was carried out
to assay levels of MAP2 (microtubule-associated protein 2) in protein
samples derived from murine embryonic (embryonic day 15) cortical
neurons (18 DIV). Kainate (100 lM, 24 h) induces signiﬁcant neu-
rodegeneration in neuronal cultures. Astrocytes co-cultured with
neurons using transwells, prior to addition of kainate, do not protect
against kainate-induced neuronal cell death. SHH-treated astrocytes,
co-cultured with neurons prior to kainate addition, delay neuronal cell
death (a). Quantiﬁcation of western bands (b) involved normalizing to
Glyceraldehyde Phosphate Dehydrogenase (GAPDH), which was also
used as a sample loading control. MAP2 A+B protein levels are
expressed as a % of controls (with and without astrocyte conditioning).
Control protein levels are represented by a red line. Signiﬁcance was
derived using students t-test (*p < 0.05, **p<0.01, ***p < 0.001).
Immunohistochemistry (c-d) showing MAP2 primary cortical neuron
cultures, co-cultured with astrocytes (c). Neurodegeneration is
observed as lack of MAP2-positive staining (d) after addition of
kainate. SHH-treated astrocytes delay kainate-induced neurodegen-
eration (e). Error bars represent standard error of the mean (SEM)
Scale bar = 100 lm. N = 3 independent cultures.
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To corroborate western blot data, equivalent experiments
were conducted using MAP2 immunohistochemistry
(Fig. 6c). Neurons conditioned with untreated astrocytes
show drastic MAP2 loss (Fig. 6d). Neuronal cultures con-
ditioned with SHH-treated astrocytes show more MAP2-
positive cells indicating the protective effect of SHH-treated
astrocytes (Fig. 6e). Kainate also caused noticeable neuronal
blebbing indicative of neuronal degeneration (Fig. 6d) which
is improved with the addition of SAG (Fig. 6e). Quantiﬁca-
tion of ﬂuorescence revealed that SHH-sensitive astrocytes
increase MAP2 levels in comparison to neurons conditioned
with untreated astrocytes, treated with kainic acid (p = 0.04,
n = 3, Figure S2).
Discussion
We show that SHH pathway activation causes elongation
of astrocytes, along with decreases in two markers of
mature astrocytes: GLT-1 and GFAP. Our results conﬁrm
that astrocytes are sensitive to SHH agonists. SHH
signalling upstream of Gli-1 is mediated by p38 MAPK
in primary cortical astrocytes (Atkinson et al. 2009) and
these kinases are documented to have multiple functions,
including activation of NFjB signalling pathways. Our
results also conﬁrm that SHH signals transform astrocytes
and increase proliferation, as previously described (Sirko
et al. 2013). Since Gli1 but not Gli2 or Gli3 are regulated
by SHH agonists, our results suggest that the SHH effects
are mediated via Gli1 contrary to previous published
observations, which show Gli2-mediated effects in astro-
cytes (Yang et al. 2012; Chechneva et al. 2014). Other
research, however, shows that Gli1 up-regulates Ptch1
target genes in both astrocytomas and medulloblastomas,
but Cyclin D2, Plakoglobin, paired box protein Pax-6, and
NKX2.2, only in medulloblastomas. This indicates that
SHH signalling is also different between pathologies (Shahi
et al. 2010).
We show for the ﬁrst time SHH regulation of GLT-1 in
astrocytes. GLT-1 is a plasma membrane protein responsible
for L-glutamate homoeostasis in the CNS preventing excito-
toxicity during synaptic transmission (Danbolt 2001; Marti-
nez-Lozada et al. 2016). While reduction in GLT-1 has been
associated with neuronal damage (Rothstein et al. 1996),
other studies have suggested that increasing GLT-1 after
pathology can have adverse effects (Li et al. 2014). Loss of
the glutamate transporter, GLT-1 induced by SHH agonists
was transient, with SHH pathway activation causing an
increase in GLT-1 transcript levels leading to recovery of
GLT-1 within 24 h. These data show an increased protein
turnover of GLT-1 accounting for the loss by 12 h and that
this loss is corrected through increased GLT-1 transcription.
Reduced GLT-1 following SHH may contribute to excito-
toxic neuronal damage, through reduced ability of astrocytes
to take up glutamate, or conversely reduced GLT-1 may
result in less astrocyte glutamate release that is dependent on
transporter reversal. Since SHH-treated astrocytes suppress
neuronal ﬁring and promote neuroprotection to an excito-
toxic stimulus, we do not believe GLT-1 regulation to be the
determinant of the astrocyte SHH effects on neurones. SHH
treatment of astrocytes caused a decrease in GFAP expres-
sion that was independent of changes in GFAP mRNA
levels. Our ﬁndings suggest that SHH signalling is a brake to
astrogliosis, consistent with the suggestion of Garcia et al.
(2010) who showed that disrupting SHH produced mild
astrogliosis. Astrogliosis, is associated with morphological
changes, and up-regulation of the intermediate ﬁlament
protein GFAP (Eddleston and Mucke 1993; Pekny and
Nilsson 2005) (Middeldorp and Hol 2011), and the current
work shows SHH affects these features. Recent reports
suggest GFAP reduction, combined with morphological
changes indicate a form of astrocyte de-differentiation (Sirko
et al. 2013). This de-differentiation has been demonstrated
both in vitro (using Transforming growth factor alpha
(TGFa)) (Zhou et al. 2001; Sharif et al. 2007) and in vivo
using SHH (Sirko et al. 2013). This phenomenon is inter-
preted as the ability of mature astrocytes to transform into
multipotent self-renewing stem cells (Lang et al. 2004; Yang
et al. 2009). Our data show that astrocytes undergo a robust
change in phenotype when stimulated with SHH agonists.
As well as characterising some of the phenotypic and
biochemical effects of SHH pathway activation on astrocytes,
we tested the functional effect of the SHH agonist SAG on
astrocytes in regulation of neuronal network activity. We
show that neurons become hyperexcitable following SAG
administration, in a concentration-dependent manner and, at
higher concentrations, SHH caused neuronal cell death as
visualized by MAP2 staining. This suggests that SHH
signalling requires tight control to avoid highly detrimental
effects to neurons. In astrocyte-neuron co-cultures, SHH
pathway activation by SAG no longer stimulated neurones,
but instead inhibited neuronal ﬁring frequency. We showed
that this inhibition was dependent on metabolically active
astrocytes since ethylﬂuoroacetate abolished the inhibitory
effect of SHH pathway activation on suppression of neuronal
ﬁring in co-cultures. These results show that the astrocyte-
mediated inhibition of neuronal excitability is not because of
sequestration of SHH agonists, but requires a factor, currently
not identiﬁed, that is dependent on active astrocytes. In
support of this notion, recent evidence shows that hedgehog
pathway signalling can control the release of D-serine,
glutamate and ATP from cerebellar astrocytes (Okuda et al.
2016).
To extend our understanding of the inﬂuence of SHH-
treated astrocytes on neurons, we used Alvetex well inserts in
neuroprotection assays. Such inserts allow culture of astro-
cytes and neurons in the same culture vessel without physical
contact. Our results show that SHH-treated astrocytes protect
neurons from kainate-induced cell death as determined by
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assaying MAP2 loss. These in vitro results correlate and
extend previous in vivo research which has shown that SHH
signalling is protective, reducing infarct size in stroke
(Chechneva et al. 2014) and protecting against kainic acid
induced neurodegeneration (Pitter et al. 2014). Furthermore,
our use of transwells to physically separate astrocytes from
neurons without the confounding effect of SAG in the media
shows that this protection is mediated through factors
secreted from SAG-treated astrocytes and not direct astro-
cyte-neuron interactions or by SAG effects on neurones
directly. Our results suggest that the reduction in astrocyte
reactivity caused by SHH can directly inﬂuence neuronal
survival.
As previously discussed, the morphological (shape
change) and biochemical (GFAP, GLT-1) changes con-
ferred by SHH pathway activation are reminiscent of
SHH-induced reduction in astrocyte reactivity (GFAP
levels) observed in vivo, and we note that this phenotypic
change in astrocytes is accompanied by increased neuro-
protection. There is a signiﬁcant evidence base to associate
astrocyte phenotype as measured by GFAP levels with
neurodegeneration. Multiple reports show reactive astro-
cytes exacerbate ongoing pathology in various CNS
disorders like epilepsy (Zhu et al. 2012; Robel et al.
2015), motor neuron disease (Diaz-Amarilla et al. 2011)
and Alzheimer’s disease (AD) (Steele and Robinson 2012).
We also note there is contrary evidence suggesting that
reactive astrocytes, particularly during glial scar formation,
are neuroprotective (Faulkner et al. 2004; Sofroniew 2009).
Our present ﬁndings, together with evidence that astrocytes
are enriched in the proteins essential for SHH signalling
suggest that neuronal SHH is an important physiological
cue for astrocytes in the normal CNS, that mediates
astrocyte-neuron communication to help limit neuronal
excitability and confer neuroprotection.
In pathological conditions, where astrocytes become
reactive they can themselves secrete SHH (Yang et al.
2012; Pitter et al. 2014), which may compensate for lost
neuronal SHH. SHH is elevated after CNS injury (Amanku-
lor et al. 2009). We propose that neuronal SHH acts as a
homeostatic signal, providing information about the local
microenvironment to astrocytes. Loss of this signal, when
neurons are damaged or die, provides a physiological cue,
informing astrocytes about the change in the microenviron-
ment and causing astrocytes to become reactive and
themselves secrete SHH that can induce astrocyte cell
division, reduce reactivity and induce a more protective
phenotype.
In summary we show that, in vitro, SHH signals through
astrocytes to alter their phenotype, suppress neuronal ﬁring
and protect neurons from excitotoxic damage. Our ﬁndings
lead to the hypothesis, supported by other published evidence
that SHH is an endogenous neuroprotective signal, which
acts through astrocytes.
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